Trial Profile
Testing the Effect of Raltegravir on Persistent de Novo HIV Infection in Virologic Responders to Antiretroviral Therapy ( RALNOVO )
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Biomarker; Pharmacodynamics
- Acronyms RALNOVO
- 05 Jul 2021 Status changed from recruiting to completed.
- 04 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
- 25 Nov 2015 New trial record